By Lila Rouland | Published on August 21, 2025 | 2 min read
#Alzheimer
#CognitiveResilience
Alzheimer’s
disease (AD) remains the leading cause of dementia, characterized by
progressive memory loss and neuronal degeneration. While the accumulation of
amyloid plaques and tau tangles is well established, the epigenetic mechanisms
underlying neuronal vulnerability and resilience are still poorly understood.
In this
landmark study, researchers created a single-cell multi-omic atlas of 3.5
million cells from 384 post-mortem brain samples, covering six brain regions
from 111 individuals with and without AD.
The work
integrates snATAC-seq, RNA-seq, and multiome data, enabling the mapping of over
one million cis-regulatory elements (cCREs) and 123 regulatory modules across 67
cellular subtypes. This unprecedented dataset reveals how epigenomic
instability, nuclear compartment disruption, and transcriptional dysregulation
fuel AD progression, while preserved stability supports cognitive resilience.
Mapping the
brain epigenome: a region-by-region exploration
The study
focused on six key regions: entorhinal cortex (EC), hippocampus (HC),
prefrontal cortex (PFC), middle temporal cortex (MTC), angular gyrus (AG), and
thalamus (TH). These areas represent both early- and late-stage vulnerable
regions in AD progression.
Cells were
hierarchically classified into seven main classes (excitatory neurons,
inhibitory neurons, oligodendrocytes, astrocytes, microglia, oligodendrocyte
progenitor cells [OPCs], and vascular cells), and further subdivided into 67
subtypes.
Analysis of
chromatin accessibility, transcription factor (TF) motifs, and cCRE modules
highlighted region- and cell type–specific regulatory networks.
Crucially, genome-wide
nuclear compartmentalization was investigated. In a healthy brain, chromatin
alternates between active compartments (gene-rich, accessible) and repressive
compartments (silent, lamina-associated). In AD, a widespread rewiring occurs:
repressive chromatin becomes active and vice versa—particularly in the EC and
HC.
Epigenomic
erosion: correlation with cognitive decline
1. Global epigenomic relaxation
Advanced AD samples show widespread activation of normally repressive
chromatin (e.g., chr18) and repression of normally active chromosomes
(e.g., chr19). This indicates a loss of nuclear compartment fidelity and transcriptional
precision.
2. Loss of epigenomic informationSingle-cell analyses reveal a general reduction in epigenomic information
across all cell classes, particularly in glial cells (oligodendrocytes,
OPCs, microglia) and vulnerable excitatory neurons in the EC and HC.
Superficial-layer excitatory neurons in the neocortex and SST inhibitory
neurons also show marked erosion.
3. Glial activation followed by exhaustion
Initially, glial cells gain epigenomic identity during activation.
However, under prolonged stress, they lose stability and enter exhausted
states. Activated microglia and astrocytes show a sharp drop in epigenomic
information—especially in APOE4 carriers.
4. Cognitive resilience and epigenomic preservation
Unlike pathological profiles, cognitively resilient individuals (who
maintain function despite pathology) display higher epigenomic information
across the brain. Vulnerable neurons retain stability, and activated glia
avoid exhaustion. This suggests that preservation of epigenomic integrity
underlies resilience.
Regulatory
networks: from stability to dysfunction
Stable
cells protect chromatin and the nucleus (ASTN2, RORA, VCAN), while eroded
cells activate stress and inflammation pathways (APOE, CST3, VIM). Polycomb
complexes act as epigenomic guardians.
In
practice: strengthening nuclear structure, maintaining heterochromatin, or
targeting chromatin regulators could protect neurons and preserve cognition.
This represents a promising avenue for personalized epigenetic interventions
against Alzheimer’s disease.
About the Author – Lila Rouland
Doctor of Oncology, specialized in Biotechnology and Management
With dual expertise in science and marketing, Lila brings her knowledge to the service of healthcare innovation. After five years in international academic research, she transitioned into medical and scientific communication within the pharmaceutical industry. Now working as a medical writer and content developer, she is committed to highlighting scientific knowledge and conveying it to healthcare professionals with clarity and relevance.
